muscle loss glp-1 Weight with medicines does not result in a disproportionate loss of mass or function in obese mice and humans GLP‐1 receptor agonists and muscle

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial

Key Takeaways Patents and exclusivities are different weapons

The technology transformation happening within that expansion is equally significant for anyone thinking about where peptide manufacturing is heading

a decrease in both the liver weight and hepatic triglyceride content in experimental animals was observed, thereby reconfirming the antibody's significant inhibitory effect on hepatic fat accumulation

GLP-1 drugs have been linked to several eye problems, including: Non-arteritic anterior ischemic optic neuropathy (NAION) Optic neuropathy Retinal ischemia Exacerbation of diabetic retinopathy These GLP-1 eye problems can range from mild visual field defects to complete blindness in one eye

References Bailey RA, Wang Y, Zhu V, Rupnow MFT